Precision BioSciences (NASDAQ:DTIL) Director Stanley Frankel Buys 2,700 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Stanley Frankel bought 2,700 shares of the company’s stock in a transaction on Friday, September 26th. The shares were bought at an average price of $4.97 per share, for a total transaction of $13,419.00. Following the transaction, the director owned 16,778 shares of the company’s stock, valued at approximately $83,386.66. This represents a 19.18% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Precision BioSciences Trading Up 8.4%

NASDAQ:DTIL opened at $5.52 on Wednesday. The company has a market cap of $65.08 million, a P/E ratio of -0.63 and a beta of 1.61. The stock’s fifty day moving average price is $4.87 and its two-hundred day moving average price is $4.86. Precision BioSciences, Inc. has a 1 year low of $3.61 and a 1 year high of $9.81. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.18 and a quick ratio of 5.18.

Precision BioSciences (NASDAQ:DTIL) last posted its earnings results on Thursday, August 7th. The company reported ($2.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($2.04). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $6.27 million. Precision BioSciences had a negative return on equity of 176.47% and a negative net margin of 6,205.79%. As a group, analysts expect that Precision BioSciences, Inc. will post -1.23 EPS for the current year.

Institutional Investors Weigh In On Precision BioSciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its holdings in shares of Precision BioSciences by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after acquiring an additional 4,025 shares in the last quarter. Miller Financial Services LLC purchased a new stake in shares of Precision BioSciences in the 1st quarter valued at about $48,000. Jane Street Group LLC purchased a new stake in shares of Precision BioSciences in the 4th quarter valued at about $146,000. Tejara Capital Ltd raised its holdings in shares of Precision BioSciences by 185.2% in the 1st quarter. Tejara Capital Ltd now owns 60,427 shares of the company’s stock valued at $288,000 after acquiring an additional 39,242 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in Precision BioSciences in the fourth quarter valued at $179,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.